Download MendeleyNms-P937, a 4,5-Dihydro-1H-Pyrazolo[4,3-H]Quinazoline Derivative as Potent and Selective Polo-Like Kinase 1 Inhibitor.
Beria, I., Bossi, R.T., Brasca, M.G., Caruso, M., Ceccarelli, W., Fachin, G., Fasolini, M., Forte, B., Fiorentini, F., Pesenti, E., Pezzetta, D., Posteri, H., Scolaro, A., Depaolini, S.R., Valsasina, B.(2011) Bioorg Med Chem Lett 21: 2969
- PubMed: 21470862
- DOI: https://doi.org/10.1016/j.bmcl.2011.03.054
- Primary Citation of Related Structures:
2YAC - PubMed Abstract:
As part of our drug discovery effort, we identified and developed 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as PLK1 inhibitors. We now report the optimization of this class that led to the identification of NMS-P937, a potent, selective and orally available PLK1 inhibitor. Also, in order to understand the source of PLK1 selectivity, we determined the crystal structure of PLK1 with NMS-P937. The compound was active in vivo in HCT116 xenograft model after oral administration and is presently in Phase I clinical trials evaluation.
Organizational Affiliation:
Nerviano Medical Sciences srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano, MI, Italy. italo.beria@nervianoms.com
